Fringe activist alleges GLP-1s are ‘authoritarian’ and ‘exterminate overweight individuals’
There’s a new target in the crosshairs: Ozempic. At the recent Socialism 2026 conference in Chicago, which is backed by the Democratic Socialists of America, an activist made a startling assertion. They labeled GLP-1 drugs as “fascist,” claiming these medications serve to “genocide fat people.” Da’Shaun L. Harrison, an activist from Atlanta, stated, “The political […]
How GLP-1s might be contributing to a reduction in violent crime in America
Could weight-loss drugs be impacting crime rates? It’s a question currently making waves. Violent crime in the United States has dropped significantly over the past two years, leaving experts puzzled about the reasons behind this decline. A recent study from Rutgers University hints at an intriguing possibility: GLP-1 medications, like Ozempic and Wegovy, might play […]
Inside the peptide underground market where individuals are creating their own GLP-1s and Botox
The pandemic has reshaped how many Americans view their health and the sources they trust for management. During the hardships of lockdowns, a significant number turned away from traditional healthcare providers and sought guidance from influencers instead. Now, wellness creators and regular individuals are taking their health—and looks—into their own hands. A growing underground market […]
Serena Williams opens up about her weight loss and GLP-1s.
Serena Williams Shares Weight Loss Experience Tennis superstar Serena Williams has opened up about her impressive weight loss journey, during which she shed 31 pounds with the help of GLP-1 medications. In interviews with People Magazine and “Today,” she shared her struggles after giving birth to her second child, mentioning that her health suffered significantly. […]
Ozempic, Wegovy and other GLP-1s shown to reduce alcohol-related hospitalizations
Ozempic, Wigovy and other GLP-1 drugs have been shown to counteract the effects of alcohol, a new study suggests. Glucagon-like peptide-1 receptor (GLP-1) agonists (including either semaglutide or liraglutide), which are prescribed to treat type 2 diabetes and obesity, have been reported to reduce alcohol intake when taken. Previous research has shown that. A new […]